Boehringer Ingelheim Vetmedica, Inc.
The products that make up the BIVI portfolio help animals feel better, perform better and live better. A guiding principle of the Boehringer family has always been to provide Value through Innovation to our customers. We strive to provide our customers with the most innovative vaccines and pharmaceuticals with the highest therapeutic value in the cattle, equine, pet and swine markets. We believe prevention is a better approach to animal health. Additionally, BIVI supports our customers with a wide range of services that address animal health challenges beyond the bottle. We are delivering a larger and more innovative portfolio of products and services to prevent disease and improve the health and productivity of animals around the world.
Company details
Find locations served, office locations and our distributors
- Business Type:
- Manufacturer
- Industry Type:
- Livestock
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
- Vetera - Model 4XP + WNV - Encephalomyelitis Influenza West Nile Virus Vaccine
- Ingelvac - Model ATP - Porcine Reproductive and Respiratory Syndrome Vaccine (PRRS)
- Vetera - Model 5XP - Encephalomyelitis Rhinopneumonitis Influenza Vaccine
- Ingelvac - Model AR4 - Dual-Toxoid Atrophic Rhinitis Vaccine
- Triangle - Pioneer Killed Viral Vaccine
Company profile
Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. At Boehringer Ingelheim Vetmedica our vision is simple, Value Through Innovation. And each day we work towards our vision by investing in the research and development of new products and improving existing ones, providing ongoing training and educational opportunities to our employees, hiring the best and brightest minds in animal health and understanding the customers’ needs.
The mission of Boehringer Ingelheim Vetmedica, Inc. is to benefit the health and well-being of mankind by contributing to an adequate supply of safe, nutritious food and by promoting the emotional and physical benefits arising from the human-animal bond.
Boehringer Ingelheim Vetmedica, Inc. (BIVI), is the U.S. animal health division of Boehringer Ingelheim Corporation, a family-owned company founded in 1885 in Ingelheim, Germany. Boehringer Ingelheim Corporation is an international corporation of 18 operative subsidiaries and four representative offices as well as local distributors in more than 50 countries around the globe. With its own research, production and distribution facilities, the Boehringer Ingelheim Corporation ranks among the top 20 pharmaceutical companies worldwide.
Over the past 25 years, BIVI has supported its growth through research and development of innovative products for the livestock, equine and companion animal markets. Innovation and research are the keys to BIVI success. Dedicated to improving the lives and well-being of animals, BIVI continues to seek ways to further research and develop optimum solutions for the animal health industry.
History
The pharmaceutical company Boehringer Ingelheim was founded in 1885 by Albert Boehringer (1861-1939) in Ingelheim am Rhein. From its beginnings in 1885 when it employed just 28 people in Nieder-Ingelheim, the company has since become a global enterprise.
As part of research and development activities for innovative drugs, the company focuses primarily on the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology.